Health Catalyst, Inc. (NASDAQ:HCAT) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 25.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 121,350 shares of the company’s stock after selling 40,378 shares during the period. Los Angeles Capital Management LLC owned about 0.20% of Health Catalyst worth $858,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in shares of Health Catalyst during the 3rd quarter valued at $34,000. Stoneridge Investment Partners LLC acquired a new position in shares of Health Catalyst during the fourth quarter worth about $77,000. Quadrature Capital Ltd purchased a new stake in shares of Health Catalyst in the third quarter worth about $84,000. Harbor Capital Advisors Inc. grew its stake in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after buying an additional 2,064 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at about $145,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Stock Up 6.4 %

NASDAQ:HCAT opened at $4.67 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The company has a market capitalization of $284.16 million, a price-to-earnings ratio of -3.46 and a beta of 1.34. Health Catalyst, Inc. has a one year low of $3.76 and a one year high of $9.24. The stock has a 50-day simple moving average of $5.98 and a 200 day simple moving average of $7.24.

Insider Transactions at Health Catalyst

In other news, CFO Jason Alger sold 19,599 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $163,063.68. Following the transaction, the chief financial officer now directly owns 86,712 shares in the company, valued at approximately $721,443.84. This trade represents a 18.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Linda Llewelyn sold 6,441 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total transaction of $34,974.63. Following the sale, the insider now directly owns 85,819 shares of the company’s stock, valued at approximately $465,997.17. This represents a 6.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 80,110 shares of company stock worth $596,993. 2.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HCAT has been the subject of a number of analyst reports. Piper Sandler decreased their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Stifel Nicolaus decreased their target price on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research note on Thursday. Royal Bank of Canada lowered their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday. Citigroup cut their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, Stephens restated an “equal weight” rating and set a $7.00 target price on shares of Health Catalyst in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and an average price target of $9.45.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.